fbpx
Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Ubrogepant appears to prevent acute migraine

Written by | 29 Aug 2024

Treatment with ubrogepant at the first sign of migraine onset appears to help prevent acute symptoms from developing. Researchers reported their findings on August 28 in Neurology. Author… read more.

FDA approval for IPX 203 for treatment of Parkinson’s disease to be launched as Crexont (carbidopa and levodopa) extended-release capsules – Amneal Pharma

Written by | 26 Aug 2024

Amneal Pharmaceuticals, Inc., announced that the FDA has approved Crexont (carbidopa and levodopa) extended-release capsules for the treatment of Parkinson’s disease (PD). Crexont is a novel, oral formulation… read more.

Migraine and Parkinson’s disease not linked in women

Written by | 23 Aug 2024

A new analysis of data from a large study of women’s health shows no link between a history of migraine and the risk of developing Parkinson’s disease (PD)…. read more.

MS not associated with COVID-19 relapse after vaccination

Written by | 15 Aug 2024

People with multiple sclerosis (MS) do not appear to be at an increased risk of relapse after COVID-19 vaccination, researchers reported on August 14, 2024 in Neurology. “People… read more.

Public health measures that reduce dementia risk could save up to £4bn

Written by | 7 Aug 2024

Public health interventions that tackle dementia risk factors could yield as much as £4bn in savings in England by reducing dementia rates and helping people to live longer… read more.

MHRA (UK) has approved the subcutaneous version of Ocrevus to treat patients with relapsing and primary progressive multiple sclerosis – Roche

Written by | 19 Jul 2024

The United Kingdom’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Roche’s subcutaneous version of Ocrevus (ocrelizumab subcutaneous ) to treat patients with relapsing and primary progressive… read more.

Sleep disorders in childhood increase ADHD risk

Written by | 7 Jul 2024

Epidemiologists in Spain have found a new link between childhood sleep patterns and behaviour, with implications for the understanding of attention deficit hyperactivity disorder (ADHD) in preadolescence. The… read more.

Kisunla (donanemab-azbt) approved by the FDA for the treatment of early symptomatic Alzheimer’s disease – Eli Lilly

Written by | 7 Jul 2024

The FDA approved Kisunla (donanemab-azbt, 350 mg/20 mL once-monthly injection for IV infusion), Eli Lilly and Company’s Alzheimer’s treatment for adults with early symptomatic Alzheimer’s disease (AD), which… read more.

Could preventative drug be effective in people with migraine and rebound headache?

Written by | 3 Jul 2024

A drug used to prevent migraine may also be effective in people with migraine who experience rebound headaches, according to a new study published in the June 26,… read more.

FDA accepts filing of Leqembi (lecanemab-irmb) supplemental biologics license application for IV maintenance dosing for the treatment of early Alzheimer’s disease – Eisai + Biogen

Written by | 26 Jun 2024

Eisai Co. Ltd. and Biogen Inc. announced that that the FDA has accepted Eisai’s Supplemental Biologics License Application (sBLA) for monthly lecanemab-irmb (U.S. brand name: Leqembi) intravenous (IV)… read more.

Antiseizure medications can produce life-threatening reactions

Written by | 24 Jun 2024

Targeted blood tests, asking patients about risk factors, and dose modifications can lessen the risk of potentially fatal reactions to antiseizure medications that millions of Americans take for… read more.

Cognitive test is poor predictor of athletes’ concussion

Written by | 17 Jun 2024

When college athletes are evaluated for a possible concussion, the diagnosis is based on an athletic trainer or team physician’s assessment of three things: the player’s symptoms, physical… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.